Answers are grounded in this paper and cite their sources.
This review highlights the 'oxidative paradox' in hypertension, where despite clear molecular links between reactive oxygen species and vascular dysfunction, antioxidant therapies have shown limited clinical benefit.
In both animal models and humans, increased blood pressure has been associated with oxidative stress in the vasculature, i.e. an excessive endothelial production of reactive oxygen species (ROS), which may be both a cause and an effect of hypertension. In addition to NADPH oxidase, the best characterized source of ROS, several other enzymes may contribute to ROS generation, including nitric oxide synthase, lipoxygenases, cyclo-oxygenases, xanthine oxidase and cytochrome P450 enzymes. It has been suggested that also mitochondria could be considered a major source of ROS: in situations of metabolic perturbation, increased mitochondrial ROS generation might trigger endothelial dysfunction, possibly contributing to the development of hypertension. However, the use of antioxidants in the clinical setting induced only limited effects on human hypertension or cardiovascular endpoints. More clinical studies are needed to fully elucidate this so called "oxidative paradox" of hypertension.
No takes yet. Share an insight, caveat, or question.
Puddu et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: